It’s been a crucial week for ChemoCentryx, Inc. (NASDAQ:CCXI); here’s what analysts have to say.

March 16, 2018 - By Maria Brooks

 It's been a crucial week for ChemoCentryx, Inc. (NASDAQ:CCXI); here's what analysts have to say.
Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.26, from 1.4 in 2017Q2. It turned negative, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported.
Piermont Mgmt Inc holds 27,988 shares. Paw Cap owns 160,000 shares. Moreover, Manufacturers Life The has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 21,437 shares. Panagora Asset Mngmt Inc has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Tower Rech Ltd Liability (Trc) stated it has 4,461 shares. Morgan Stanley invested in 0% or 91,749 shares. Connor Clark And Lunn Inv Limited reported 65,775 shares stake. Spark Investment Mgmt Limited Liability invested in 166,500 shares. Macquarie Grp Inc holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 8,631 shares. Landscape Capital Lc accumulated 24,939 shares. Voya Inv Management Limited Liability Co owns 15,984 shares. The Luxembourg-based Artal Group Inc has invested 0.06% in ChemoCentryx, Inc. (NASDAQ:CCXI). Arrowstreet Cap Partnership has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 500 were reported by Prelude Capital Ltd Liability Corp. Smith Asset Mgmt Grp Limited Partnership holds 27,370 shares or 0.01% of its portfolio.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. ChemoCentryx had 6 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by JMP Securities with “Buy” on Thursday, August 10. The firm earned “Sell” rating on Thursday, September 3 by Zacks. As per Tuesday, August 8, the company rating was maintained by Cowen & Co. The rating was initiated by JMP Securities on Tuesday, February 21 with “Mkt Outperform”. JP Morgan maintained the shares of CCXI in report on Tuesday, March 13 with “Overweight” rating. Zacks downgraded the stock to “Sell” rating in Monday, September 21 report. Below is a list of ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings and price target changes.

13/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $13 New Target: $16 Maintain

The stock increased 2.09% or $0.29 during the last trading session, reaching $14.14. About 354,722 shares traded or 25.92% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since March 16, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $689.56 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 39.28 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.